Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients

Authors Dalal AA, St Charles M, Petersen HV, Roberts MH, Blanchette C, Manavi-Zieverink K

Published 9 June 2010 Volume 2010:5 Pages 179—187

DOI https://doi.org/10.2147/COPD.S10988

Review by Single-blind

Peer reviewer comments 2

Anand A Dalal1, Meaghan St Charles2, Hans V Petersen2, Melissa H Roberts2, Christopher M Blanchette2, Kathy Manavi-Zieverink3

1US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, 2Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis USA; 3INC Research, Raleigh; NC, USA

Objective: To estimate the cost-effectiveness of fluticasone propionate–salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD).

Study design: Pooled economic analysis.

Methods: We performed an economic analysis of pooled data from two randomized clinical trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 μg twice daily) or salmeterol (50 μg twice daily) on exacerbation rates in patients with severe COPD. We calculated exacerbation rates and applied standardized costs to exacerbation-related health care utilization reported in the trials (office, urgent care, and emergency department visits; hospitalizations; and oral corticosteroids and antibiotics) to determine cost differences between FSC and salmeterol treatment outcomes.
Results: Annual rates of any exacerbation and moderate/severe exacerbation were lower in the FSC group than the salmeterol group (4.91 vs 5.78 and 1.32 vs 2.00 respectively, both P < 0.05). Total adjusted annual COPD related exacerbation and therapeutic costs were $4,842 (95% CI; $4,731–$4,952) in the FSC group and $5,066 (95% CI; $4,937–$5,195) in the salmeterol group.

Conclusions: FSC combination therapy is associated with reduced risk of any exacerbation and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs compared to treatment with salmeterol. This analysis demonstrates that FSC therapy may be advantageous from both a clinical and cost-benefit standpoint for patients with severe COPD.
Keywords: COPD, cost-effectiveness analysis, economic, maintenance therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]